AnaptysBio Inc
USUSDAnaptysBio Inc (LSE:0HFQ) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- anaptysbio.com
- Relazioni con gli Investitori
- ir.anaptysbio.com/
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- SAN DIEGO, United States
- Gestione
- Daniel R. Faga
- Quotata dal
- 29.01.2018 (LSE:0HFQ)
- Azioni in Circolazione
- 29.9 Mln al 2026-09-16
- Flottante
- 20.44 Mln
- Capitalizzazione di Mercato
- 1.37 Mld USD
- Insider
- 5.63%
- Investitori Istituzionali
- 105.16%
- Settore (SIC)
- Pharmaceutical Preparations
- P/E
- perdita
- P/B
- 139.4
- FCF
- 4.41 Mln USD
- Debito
- ?
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
- Utile Netto
- NAV
Descrizione
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| EcoR1 Capital, LLC | 26.36% | 7.88 Mln | 2026-06-30 |
| Blackrock Inc. | 6.17% | 1.84 Mln | 2026-06-30 |
| Tang Capital Management,… | 4.45% | 1.33 Mln | 2026-06-30 |
| State Street Corporation | 4.3% | 1.29 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 3.03% | 906 233 | 2026-06-30 |
| SPDR SERIES TRUST-State… | 2.78% | 830 300 | 2026-08-31 |
| Affinity Asset Advisors,… | 2.76% | 826 109 | 2026-06-30 |
| Sanofi | 2.75% | 821 917 | 2026-06-30 |
| Millennium Management Ll… | 2.7% | 807 316 | 2026-06-30 |
| Woodline Partners LP | 2.4% | 717 014 | 2026-06-30 |
| 683 Capital Management L… | 2.21% | 660 000 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 648 146 | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.7% | 507 270 | 2026-08-31 |
| FAGA DANIEL R (Chief Exe… | ≈1.66% | 495 965 | 2026-03-27 |
| TIAA-CREF Funds-Nuveen Q… | 0.88% | 263 840 | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.79% | 237 032 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.72% | 215 873 | 2026-07-31 |
| Federated Hermes Equity… | 0.7% | 210 000 | 2026-07-31 |
| iShares Trust-iShares Bi… | 0.68% | 204 436 | 2026-08-31 |
| Victory Portfolios III-V… | 0.63% | 187 893 | 2026-07-31 |
| Invesco Exchange-Traded… | 0.63% | 187 467 | 2026-08-31 |
| LIZZUL PAUL F. (Officer) | ≈0.14% | 42 088 | 2026-01-08 |
| SCHMID JOHN P (Director) | ≈0.13% | 37 652 | 2026-06-15 |
| MULROY DENNIS CPA (Chief… | ≈0.07% | 21 852 | 2026-01-08 |
| ORWIN JOHN A (Director) | ≈0.06% | 17 995 | 2026-09-15 |
| LOUMEAU ERIC JOSEPH (Off… | ≈0.04% | 12 835 | 2026-02-11 |
| JAIN RITA (Director) | ≈0.04% | 11 864 | 2025-06-13 |
| RENTON HOLLINGS C (Direc… | ≈0.04% | 10 995 | 2026-06-15 |
| MARQUET MAGDA (Director) | ≈0.03% | 9 930 | 2026-01-15 |
| ECOR1 CAPITAL, L.L.C. (B… | — | — | 2025-01-02 |
Accedi con Google